Lentiviral vectors for cutaneous RNA managing

Beta thalassemia gene therapy using lentiviral vectors

Recent years, allogeneic bone marrow transplantation (BMT) has proved to be the successful cure for patients with thalassemia major, however this is restricted due to limited matched-related donor. Its complications include chronic graft-versus-host disease in 5-8% of patients. So, a molecular approach, such as gene therapy for direct normal beta globin gene transmission, seems quite promising ...

CRE recombinase-inducible RNA interference mediated by lentiviral vectors.

Recently, several systems designed to trigger RNA interference by using small hairpin RNA driven by polymerase III promoters have been described. Here, we report a lentiviral-mediated small interfering RNA delivery system that can be induced by CRE recombinase. The system consists of a lentiviral vector carrying a mouse U6 promoter that is separated from a small hairpin RNA by a random DNA stuf...

Biosafety of lentiviral vectors.

The characteristics of lentiviral vectors (stable integration in non-dividing and dividing cells, long-term expression of the transgene, absence of immune response) make them ideal gene transfer vehicula for future gene therapy. However, the most potent lentiviral vectors are derived from highly pathogenic human viruses, such as HIV. We describe how the field has engineered lentivectors with in...

Lentiviral Vectors in Immunotherapy

Lentiviral transgene vectors

Transgenic animals can be broadly defined as animals that contain recombinant DNA molecules in their genome that have been introduced by human intervention (Wall, 1996). Developmental studies and clinically relevant disease models are based on transgenic laboratory animals, most commonly the mouse. In farm animals, transgenic technology is used to produce large quantities of pharmaceutically re...